[go: up one dir, main page]

PE20200732A1 - Formas de dosificacion oral y de liberacion controlada gastrorresistentes - Google Patents

Formas de dosificacion oral y de liberacion controlada gastrorresistentes

Info

Publication number
PE20200732A1
PE20200732A1 PE2019002573A PE2019002573A PE20200732A1 PE 20200732 A1 PE20200732 A1 PE 20200732A1 PE 2019002573 A PE2019002573 A PE 2019002573A PE 2019002573 A PE2019002573 A PE 2019002573A PE 20200732 A1 PE20200732 A1 PE 20200732A1
Authority
PE
Peru
Prior art keywords
controlled release
gastrore
subject
oral dosage
dosage forms
Prior art date
Application number
PE2019002573A
Other languages
English (en)
Inventor
Emmanuelle Georgi
Jay Saoud
Remy Luthringer
Sandra Werner
Nadine Noel
Original Assignee
Minerva Neurosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=62904624&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20200732(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Minerva Neurosciences Inc filed Critical Minerva Neurosciences Inc
Publication of PE20200732A1 publication Critical patent/PE20200732A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La presente descripcion se refiere a formas de dosificacion de liberacion controlada gastrorresistentes que comprenden el Compuesto (I): o una sal y/o un solvato farmaceuticamente aceptable de este, las propiedades farmacocineticas de estas formas de dosificacion, y su preparacion. Las nuevas formas de dosificacion descritas en la presente son utiles para reducir el riesgo de prolongacion QT en un sujeto y para tratar un trastorno en un sujeto que lo necesita, p. ej., un sujeto diagnosticado con esquizofrenia, por ejemplo, en el tratamiento de los sintomas negativos en un sujeto diagnosticado con esquizofrenia que tiene el genotipo CYP2D6 EM.
PE2019002573A 2017-06-21 2018-06-21 Formas de dosificacion oral y de liberacion controlada gastrorresistentes PE20200732A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762523204P 2017-06-21 2017-06-21
PCT/US2018/038853 WO2018237207A1 (en) 2017-06-21 2018-06-21 Gastro-resistant controlled release oral dosage forms

Publications (1)

Publication Number Publication Date
PE20200732A1 true PE20200732A1 (es) 2020-07-23

Family

ID=62904624

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2019002573A PE20200732A1 (es) 2017-06-21 2018-06-21 Formas de dosificacion oral y de liberacion controlada gastrorresistentes

Country Status (15)

Country Link
US (3) US11464744B2 (es)
EP (1) EP3641732A1 (es)
JP (3) JP2020525436A (es)
CN (1) CN111511353A (es)
AU (2) AU2018290287B2 (es)
BR (1) BR112019027398A2 (es)
CA (1) CA3067031A1 (es)
CL (1) CL2019003743A1 (es)
CO (1) CO2019014496A2 (es)
IL (3) IL319156A (es)
MX (1) MX2023002994A (es)
PE (1) PE20200732A1 (es)
UA (1) UA127349C2 (es)
WO (1) WO2018237207A1 (es)
ZA (1) ZA202409847B (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PH12017501007B1 (en) 2014-12-02 2024-07-03 Mitsubishi Tanabe Pharma Corp Compositions comprising 2-((1-(2 - (4-fluorophenyl) -2- oxoethyl) piperidin-4-yl) methyl) isoindolin-1-one for treating schizophrenia
PE20200732A1 (es) 2017-06-21 2020-07-23 Minerva Neurosciences Inc Formas de dosificacion oral y de liberacion controlada gastrorresistentes
CA3108882A1 (en) 2018-08-21 2020-02-27 Minerva Neurosciences, Inc. Use of roluperidone to treat negative symptoms and disorders, increase neuroplasticity, and promote neuroprotection
IT201800011125A1 (it) * 2018-12-14 2020-06-14 Dpl Pharma S P A Composizioni farmaceutiche orali solide comprendenti matrici monolitiche complesse per la somministrazione cronotropica di medicamenti nel tratto gastroenterico
AU2023217097A1 (en) 2022-02-14 2024-08-29 Minerva Neurosciences, Inc. Use of roluperidone in preventing relapse in schizophrenia patients
WO2025090588A1 (en) 2023-10-24 2025-05-01 Minerva Neurosciences, Inc. Roluperidone for the treatment of lysosomal storage disorders and their symptoms

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0325063B1 (en) 1988-01-21 1994-03-09 Merrell Dow Pharmaceuticals Inc. Use of 1,4-disubstituted-piperidinyl compounds in the manufacture of a medicament for the treatment of insomnia
EP0497843A4 (en) 1989-10-27 1992-09-23 The Du Pont Merck Pharmaceutical Company (n-phthalimidoalkyl) piperidines
WO1993022309A1 (en) 1992-04-23 1993-11-11 Merrell Dow Pharmaceuticals Inc. 4-imidomethyl-1-[2'phenyl-2'oxoethyl-] piperidines as serotonin 5ht2-antagonists, their preparation and use in therapy
DK1260512T3 (da) 2000-02-29 2007-11-05 Mitsubishi Pharma Corp Hidtil ukendte, cykliske amidderivater
SI1345595T1 (sl) 2000-09-29 2007-08-31 Solvay Pharm Bv Farmacevtska oblika s podaljĺ anim sproĺ äśanjem, ki je neodvisna od ionske jakosti
JP5547865B2 (ja) 2003-10-29 2014-07-16 ワイス・エルエルシー アプリンドルおよびその誘導体を含む持続放出型医薬組成物
MY147202A (en) * 2003-11-26 2012-11-14 Novartis Ag Compositions comprising organic compounds
TW200616608A (en) 2004-07-09 2006-06-01 Forest Laboratories Memantine as adjunctive treatment to atypical antipsychotics in schizophrenia patients
EP1891002B1 (en) 2005-06-06 2012-05-30 Merck Sharp & Dohme Limited Cyclohexanesulfonyl derivatives as glyt1 inhibitors to treat schizophrenia
CN101378752A (zh) 2006-02-07 2009-03-04 田边三菱制药株式会社 4-酰氨基吡啶衍生物介导的神经发生
CA2569776A1 (en) 2006-02-17 2007-08-17 Kos Life Sciences, Inc. Low flush niacin formulation
TW200817400A (en) 2006-05-30 2008-04-16 Elbion Ag Pyrido [3,2-e] pyrazines, their use as inhibitors of phosphodiesterase 10, and processes for preparing them
CN101273982A (zh) 2007-03-30 2008-10-01 田边三菱制药株式会社 预防和/或治疗抑郁症的药物
GB2462611A (en) 2008-08-12 2010-02-17 Cambridge Lab Pharmaceutical composition comprising tetrabenazine
EP2246331A1 (en) 2009-04-24 2010-11-03 Westfälische Wilhelms-Universität Münster NR2B-selective NMDA-receptor antagonists
CA2762179A1 (en) 2009-05-18 2010-11-25 Sigmoid Pharma Limited Composition comprising oil drops
JP5669837B2 (ja) 2010-06-16 2015-02-18 帝人ファーマ株式会社 放出制御型の有核錠剤
SMT202300413T1 (it) 2010-07-20 2024-01-10 Minerva Neurosciences Inc Metodi di utilizzo di derivati di ammide ciclica per trattare schizofrenia e relativi sintomi
US8937900B2 (en) 2010-07-20 2015-01-20 Qualcomm Incorporated Enhancing pilot channel transmission in TD-SCDMA multicarrier systems using secondary carrier frequencies
DK2595485T3 (da) 2010-07-20 2022-05-30 Minerva Neurosciences Inc Fremgangsmåder til anvendelse af cykliske amidderivater til behandling af sigma-receptormedierede forstyrrelser
US20120040008A1 (en) * 2010-08-11 2012-02-16 Ashish Chatterji Pharmaceutical compositions of metabotropic glutamate 5 receptor (mglu5) antagonists
EP2468264A1 (en) * 2010-12-27 2012-06-27 Laboratorios Liconsa, S.A. Oral pharmaceutical tablet for controled release of mesalazine and process for obtaining it
US9737531B2 (en) 2012-07-12 2017-08-22 Glytech, Llc Composition and method for treatment of depression and psychosis in humans
WO2012123922A1 (en) 2011-03-17 2012-09-20 Lupin Limited Controlled release pharmaceutical compositions of selective serotonin reuptake inhibitor
EP3718546A1 (en) * 2011-08-16 2020-10-07 Cardiora Pty Ltd Controlled-release formulation
US9907755B2 (en) * 2013-03-14 2018-03-06 Therabiome, Llc Targeted gastrointestinal tract delivery of probiotic organisms and/or therapeutic agents
CN104586771B (zh) * 2013-10-30 2018-01-16 广州朗圣药业有限公司 一种盐酸坦洛新缓释微丸制剂
SG10201809518QA (en) 2014-04-30 2018-11-29 Incyte Corp Processes of preparing a jak1 inhibitor and new forms thereto
US10208046B2 (en) 2014-05-16 2019-02-19 Takeda Pharmaceutical Company Limited Nitrogen-containing heterocyclic compound
US10179776B2 (en) 2014-06-09 2019-01-15 Intra-Cellular Therapies, Inc. Compounds and methods of use to treat schizophrenia
BR112017002761A2 (pt) * 2014-08-13 2017-12-19 Cedars Sinai Medical Center composições anti-metanogênicas e usos das mesmas
PH12017501007B1 (en) * 2014-12-02 2024-07-03 Mitsubishi Tanabe Pharma Corp Compositions comprising 2-((1-(2 - (4-fluorophenyl) -2- oxoethyl) piperidin-4-yl) methyl) isoindolin-1-one for treating schizophrenia
JP6855469B2 (ja) * 2015-10-16 2021-04-07 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． 消化器標的療法のための処方物を調製するための工程
CN109689055A (zh) 2016-05-25 2019-04-26 田边三菱制药株式会社 用于治疗非精神分裂症患者中的阴性症状的组合物和方法
PE20200732A1 (es) 2017-06-21 2020-07-23 Minerva Neurosciences Inc Formas de dosificacion oral y de liberacion controlada gastrorresistentes
CA3108882A1 (en) 2018-08-21 2020-02-27 Minerva Neurosciences, Inc. Use of roluperidone to treat negative symptoms and disorders, increase neuroplasticity, and promote neuroprotection
WO2020264486A1 (en) 2019-06-28 2020-12-30 Teva Czech Industries S.R.O Solid state forms of roluperidone and salts thereof
AU2023217097A1 (en) 2022-02-14 2024-08-29 Minerva Neurosciences, Inc. Use of roluperidone in preventing relapse in schizophrenia patients

Also Published As

Publication number Publication date
IL319156A (en) 2025-04-01
CN111511353A (zh) 2020-08-07
UA127349C2 (uk) 2023-07-26
CA3067031A1 (en) 2018-12-27
JP2023175778A (ja) 2023-12-12
IL271606A (en) 2020-02-27
RU2020102015A (ru) 2021-07-21
JP2025134828A (ja) 2025-09-17
IL308650B1 (en) 2025-04-01
AU2024219717A1 (en) 2024-10-03
WO2018237207A1 (en) 2018-12-27
EP3641732A1 (en) 2020-04-29
US20220401368A1 (en) 2022-12-22
US11464744B2 (en) 2022-10-11
IL308650A (en) 2024-01-01
IL271606B1 (en) 2024-01-01
US12048768B2 (en) 2024-07-30
CO2019014496A2 (es) 2020-04-01
JP2020525436A (ja) 2020-08-27
IL308650B2 (en) 2025-08-01
IL271606B2 (en) 2024-05-01
MX2023002994A (es) 2023-09-15
US20250009665A1 (en) 2025-01-09
ZA202409847B (en) 2025-09-25
BR112019027398A2 (pt) 2020-07-07
AU2018290287A1 (en) 2020-01-16
US20190038561A1 (en) 2019-02-07
CL2019003743A1 (es) 2020-07-03
RU2020102015A3 (es) 2021-10-04
AU2018290287B2 (en) 2024-06-13

Similar Documents

Publication Publication Date Title
CO2019014496A2 (es) Formas de dosificación oral y de liberación controlada gastrorresistentes
MX2015011473A (es) Compuesto de fosforamidato de nucleosido novedoso y su uso.
CO2020003478A2 (es) Inhibidores de la ectonucleótido pirofosfatasa-fosfodiesterasa 1 (enpp-1) y usos de los mismos
CY1121735T1 (el) 7-benzyλ-10-(2-meθyλobenzyλ)-2,6,7,8,9,10-eξaϋδpoϊmiδazo[1,2-α]πυριδο[4,3-d]πυριμιδιν-5(3η)-ονη για χρηση στην αγωγη του καρκινου
MX2021005561A (es) Rad1901 para usarse en el tratamiento de cancer en sujetos con cancer positivo a receptor de estrogeno alfa resistente a farmaco.
ECSP18087352A (es) Formulaciones de un inhibidor de lsd1
MX2019007474A (es) Gamma-carbolinas fusionadas con heterociclos sustituidas con deuterio.
MX385678B (es) Gamma-carbolinas heterocíclicas fusionadas sustituidas, composiciones farmacéuticas y métodos de uso.
MX2015015228A (es) Sobetirome en el tratamiento de enfermedades de mielinizacion.
MX2018012379A (es) Degradadores de proteinas de bromodominio y dominioextraterminal (bet).
MX2020007485A (es) Compuestos antiproliferativos y metodos de uso de los mismos.
MX2021007679A (es) Anticuerpos humanos para hemaglutinina de influenza.
AR101740A1 (es) Terapia de combinación y composiciones
GT201500086A (es) Análogos de 2'-cloro nucleósido para infección por vhc
CL2013002417A1 (es) Compuestos derivados de fluoropiridinona; composición farmacéutica que los comprende; y su uso en el tratamiento de infecciones bacterianas.
MX2019009114A (es) Sal de hemisulfato de nucleotido para el tratamiento del virus de hepatitis c.
AR094707A1 (es) Compuesto de quinazolin-4-amina, composición farmacéutica que lo comprende y su uso para el tratamiento de una enfermedad mediada por la quinasa rip2
MX2018003893A (es) Moduladores del receptor p2x3 y p2x2/3 de diaminopirimidina para usarse en el tratamiento de la tos.
NI201800071A (es) Compuestos de isoindol
CU24519B1 (es) Derivados de aminotiazol útiles como agentes antivíricos
ECSP16084317A (es) Formulaciones farmacéuticas, procesos para la preparación y métodos de uso
AR099558A1 (es) Régimen de dosaje del compuesto fgf-18
CL2016002879A1 (es) Composiciones farmacéuticas para tratar enfermedades infecciosas
CL2016000300A1 (es) Métodos terapéuticos
MX2018014080A (es) Uso de compuesto de carbamato para prevenir o tratar fibromialgia o sindrome funcional asociado con fibromialgia.